Axiom offers to pay biotechs to run drug programs while they keep 100% of assets
cjmaddison · x · 2026-11-22
AI drug-discovery firm Axiom says it's looking to partner with preclinical and clinical biotechs — and will pay them to run their drug programs, or partner on existing datasets. Axiom claims to cover the full loop: synthesis, potency, ADME, and 'the most predictive toxicity and safety assays in the world.'
The deal structure: the biotech retains 100% ownership of the asset, while Axiom shares ownership of the underlying data — a 'data-for-cash plus experimental outsourcing' model for programs that want to monetize development while keeping all upside.
More from Apps
- Snap Shot Golf turns any photo into a playable golf hole in a 595KB iOS game — soleio · 2026-11-22
- Two Korean Students Built the Anti-AI Essay Tool: It Only Checks If Your Supplement Answers the Prompt — PJ-Group-korea · 2026-11-22
- Karpathy's LLM Wiki idea comes alive: lumimax maps 2,000 Game of Thrones characters — SucceededMind · 2026-11-22
- Day 1 Recap of GEO Conference 2025: 15 Speakers' Pitfalls and Playbooks — vista8 · 2026-11-22
- Using Claude Code to test WiFi room by room cut bad signal by ~76% — doooyle · 2026-11-22
- Wrap, a Mac recorder that logs what you did so agents can edit, pushes toward 1.0 — therealdanvega · 2026-11-22